Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Charles River Laboratories
CRL
$10.9B
| $236M | 0.21% |
1,664,500
-221,200
| -12% | -$30M |
|
102
Markel Group
MKL
$25B
| $236M | 0.21% |
216,371
-12,040
| -5% | -$12.6M |
|
103
CSX Corp
CSX
$98.6B
| $235M | 0.21% |
9,110,700
+6,694,500
| +277% | +$172M |
|
104
WIX.com
WIX
$2.15B
| $233M | 0.2% |
1,637,300
-200,400
| -11% | -$27M |
|
105
Scotiabank
BNS
$106B
| $232M | 0.2% |
4,268,600
+358,200
| +9% | +$19.1M |
|
106
Sinclair Inc
SBGI
$974M
| $230M | 0.2% |
4,291,227
+1,072,664
| +33% | +$54.4M |
|
107
Ericsson
ERIC
$30.7B
| $222M | 0.2% |
23,362,900
+2,259,100
| +11% | +$21.9M |
|
108
Wells Fargo
WFC
$261B
| $221M | 0.19% |
4,661,211
+1,816,711
| +64% | +$85M |
|
109
Kinross Gold
KGC
$28.5B
| $220M | 0.19% |
56,711,483
-1,997,173
| -3% | -$6.73M |
|
110
Ryanair
RYAAY
$29.5B
| $218M | 0.19% |
8,491,548
-87,500
| -1% | -$2.48M |
|
|
ALXN
111
DELISTED
Alexion Pharmaceuticals
ALXN
| $215M | 0.19% |
1,642,542
+840,742
| +105% | +$108M |
|
112
Medtronic
MDT
$107B
| $215M | 0.19% |
+2,206,541
| New | +$201M |
|
|
HZNP
113
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $211M | 0.19% |
8,754,275
+896,500
| +11% | +$22.7M |
|
114
Newmont
NEM
$98.2B
| $208M | 0.18% |
5,403,498
+28,098
| +0.5% | +$950K |
|
115
Comcast
CMCSA
$79.1B
| $207M | 0.18% |
+4,902,776
| New | +$207M |
|
116
Cogent Communications
CCOI
$594M
| $203M | 0.18% |
3,423,700
+47,300
| +1% | +$2.71M |
|
117
HSBC
HSBC
$355B
| $203M | 0.18% |
4,866,027
+1,844,756
| +61% | +$77.3M |
|
|
OPTU
118
Optimum Communications Inc
OPTU
$316M
| $203M | 0.18% |
8,340,700
-143,300
| -2% | -$3.4M |
|
119
Berkshire Hathaway Class B
BRK.B
$1.07T
| $199M | 0.18% |
935,100
-401,800
| -30% | -$83.1M |
|
120
Telus
TU
$16B
| $199M | 0.18% |
10,796,200
-551,000
| -5% | -$10.2M |
|
121
AvalonBay Communities
AVB
$27.1B
| $196M | 0.17% |
964,614
-504,300
| -34% | -$102M |
|
122
Sony
SONY
$123B
| $194M | 0.17% |
18,560,000
+2,865,000
| +18% | +$28.1M |
|
123
CME Group
CME
$92.2B
| $192M | 0.17% |
991,419
-876,789
| -47% | -$162M |
|
124
Roku
ROKU
$21.1B
| $192M | 0.17% |
2,115,800
-739,800
| -26% | -$59.4M |
|
125
Douglas Emmett
DEI
$2.06B
| $191M | 0.17% |
4,798,800
+706,200
| +17% | +$28.9M |
|
Similar funds
Renaissance Technologies's Q2 2019 Portfolio in Review
As of Q2 2019, Renaissance Technologies held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Renaissance Technologies's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Renaissance Technologies's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Renaissance Technologies added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Renaissance Technologies's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Renaissance Technologies fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Renaissance Technologies's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Renaissance Technologies opened 495 new positions and closed 397 in Q2 2019.
- Renaissance Technologies's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.